zonisamide has been researched along with Abnormalities, Drug-Induced in 5 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 8.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 5.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| "05) of an increased hazard of fetal malformation associated with exposure to valproate, carbamazepine, topiramate, zonisamide, and with conception after assisted fertilization, but a reduced hazard in the offspring of women who continued to smoke during pregnancy." | 4.31 | Specific fetal malformations following intrauterine exposure to antiseizure medication. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 4.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "Zonisamide safety was evaluated based on a postmarketing surveillance study of patients treated for 1-3 years." | 1.34 | Erratum to "Safety of zonisamide therapy: prospective follow-up survey.". ( Ohtahara, S; Yamatogi, Y, 2007) |
| "Zonisamide safety was evaluated based on a postmarketing surveillance study of patients treated for 1-3 years." | 1.32 | Safety of zonisamide therapy: prospective follow-up survey. ( Ohtahara, S; Yamatogi, Y, 2004) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 1.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vajda, F | 1 |
| O'Brien, T | 1 |
| Graham, J | 1 |
| Hitchcock, A | 1 |
| Perucca, P | 1 |
| Lander, C | 1 |
| Eadie, M | 1 |
| McCluskey, G | 1 |
| Kinney, MO | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Bromley, R | 1 |
| MacKillop, L | 1 |
| Heath, C | 1 |
| Liggan, B | 1 |
| Murphy, S | 1 |
| Delanty, N | 1 |
| Irwin, B | 1 |
| Campbell, E | 1 |
| Morrow, J | 1 |
| Hunt, SJ | 1 |
| Craig, JJ | 1 |
| Ohtahara, S | 2 |
| Yamatogi, Y | 2 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Amano, Y | 1 |
| Egawa, I | 1 |
5 other studies available for zonisamide and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Specific fetal malformations following intrauterine exposure to antiseizure medication.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Carbamazepine; Female; Humans; Male; Pregna | 2023 |
Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Ireland; | 2021 |
Safety of zonisamide therapy: prospective follow-up survey.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Pr | 2004 |
Erratum to "Safety of zonisamide therapy: prospective follow-up survey.".
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Pr | 2007 |
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anencephaly; Anticonvulsants; Epilepsy; Female; Humans; Infant, | 1996 |